Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes of Patients Receiving Temporary Circulatory Support Before Durable Ventricular Assist Device.
Shah P, Pagani FD, Desai SS, Rongione AJ, Maltais S, Haglund NA, Dunlay SM, Aaronson KD, Stulak JM, Davis MB, Salerno CT, Cowger JA; Mechanical Circulatory Support Research Network. Shah P, et al. Among authors: davis mb. Ann Thorac Surg. 2017 Jan;103(1):106-112. doi: 10.1016/j.athoracsur.2016.06.002. Epub 2016 Aug 28. Ann Thorac Surg. 2017. PMID: 27577033
1,25-Dihydroxyvitamin D3 Suppresses Prognostic Survival Biomarkers Associated with Cell Cycle and Actin Organization in a Non-Malignant African American Prostate Cell Line.
Johnson JR, Martini RN, Yuan YC, Woods-Burnham L, Walker M, Ortiz-Hernandez GL, Kobeissy F, Galloway D, Gaddy A, Oguejiofor C, Allen B, Lewis D, Davis MB, Kimbro KS, Yates CC, Murphy AB, Kittles RA. Johnson JR, et al. Among authors: davis mb. Biology (Basel). 2024 May 15;13(5):346. doi: 10.3390/biology13050346. Biology (Basel). 2024. PMID: 38785827 Free PMC article.
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Olopade OI, Davis MB, Martin ML, Bargonetti J. Madorsky Rowdo FP, et al. Among authors: davis mb. Cancer Lett. 2024 Mar 1;584:216608. doi: 10.1016/j.canlet.2024.216608. Epub 2024 Jan 9. Cancer Lett. 2024. PMID: 38199587 Free article.
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Olopade OI, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Davis MB, Martin ML, Bargonetti J. Madorsky Rowdo FP, et al. Among authors: davis mb. bioRxiv [Preprint]. 2023 Jun 22:2023.06.22.544406. doi: 10.1101/2023.06.22.544406. bioRxiv. 2023. PMID: 38076873 Free PMC article. Updated. Preprint.
277 results